Equities research analysts at StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report issued on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Titan Pharmaceuticals stock opened at $3.41 on Friday. The stock has a fifty day moving average of $3.57 and a 200-day moving average of $4.27. Titan Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- Technology Stocks Explained: Here’s What to Know About Tech
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Stocks to Buy While Others Stay on the Sidelines
- Quiet Period Expirations Explained
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
